Edible berry extracts rich in anthocyanins possess a broad spectrum of therapeutic, pharmacologic and anti-carcinogenic properties. Anthocyanins are naturally occurring compounds that have antioxidant, anti-carcinogenic and anti-angiogenic properties. OptiBerry®, a synergistic blend of six standardized, anthocyanin-rich edible berry extracts, was developed after screening a variety of extract combinations for their antioxidant capacity, cellular uptake, safety, and the ability to block undesirable blood vessel growtha key event in tumor formation. To evaluate the in vivo antioxidant properties of OptiBerry®, animals deficient in vitamin E (an antioxidant) were exposed to a hyperbaric oxygen (HBO) system to induce oxidation. Glutathione, an important antioxidant, was protected in the lungs and liver of animals fed OptiBerry® for 8 weeks prior to HBO exposure. In addition, feeding OptiBerry® for 2 weeks before exposure to HBO significantly protected animals against whole-body oxidation compared to control animals. Whole-body oxidation was measured by electron paramagnetic resonance, a state-of-the-art imaging technique. To further assess safety, OptiBerry® was evaluated in acute oral and dermal tests, as well as in eye and skin irritation tests, in animals. The oral and skin LD50 (acute toxicity) values were found to be greater than 5,000 and 2,000 milligrams per kilogram of body weight, respectively, indicating very low potential for toxicity. No changes in body weight or adverse effects were seen in histopathological evaluation. In primary irritation tests, OptiBerry® was observed to be only slightly or minimally irritating to the skin and eye, respectively. These findings indicate that OptiBerry® is safe and offers whole-body antioxidant protection under the present test conditions.
OptiBerry® Shown to Inhibit Pathogenic Heliobacter pylori Bacteria In Vitro
OptiBerry® is a synergistic blend of six standardized anthocyanin berry extracts that has demonstrated antioxidant capacity in vitro and anti-angiogenic properties in vivo. The present study evaluates the effects of various berry extracts on Helicobacter pylori, a common bacterium that plays a role in the formation of peptic and duodenal ulcers and chronic gastritis. Conventional therapy for H. pylori infection consists of treatment with certain antibiotics and acid-suppressing agents. One of the major reasons for conventional treatment failure is the growing resistance to antibiotics such as clarithromycin. This has sparked increasing interest in developing natural plant extracts, which can serve as adjuncts to conventional treatment. Diluted cell suspensions from cultured H. pylori were incubated with varying concentrations of strawberry, raspberry, cranberry, elderberry, blueberry, bilberry and OptiBerry®. Diluted samples from each of the mixtures were cultured again and the number of H. Pylori colonies determined. Serially diluted cell suspensions with added berry extracts were also exposed to clarithromycin, then cultured. Quantification of the H. pylori colonies showed that all berry extracts significantly inhibited H. pylori compared to controls (p<0.05). The extracts also increased the bacterias susceptibility to clarithromycin, with OptiBerry® exhibiting the strongest effects at the lowest concentration tested.